

Reference list

NK cells

Human NK cells

NK Cell Isolation Kit

Baessler, T. *et al.* (2010) CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. *Blood* 115: 3058–3069.

Bellora, F. *et al.* (2010) The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. *Proc. Natl. Acad. Sci USA*. Epub ahead of print, Nov. 30.

Carbone, T. *et al.* (2010) CD56^{high}CD16⁻CD62L⁻ NK cells accumulate in allergic contact dermatitis and contribute to the expression of allergic responses. *J. Immunol.* 184: 1102–1110.

Lee, S. H. *et al.* (2010) Suppressor of cytokine signaling 2 regulates IL-15–primed human NK cell function via control of phosphorylated Pyk2. *J. Immunol.* 185: 917–928.

Maniar, A. *et al.* (2010) Human $\gamma\delta$ T lymphocytes induce robust NK cell–mediated antitumor cytotoxicity through CD137 engagement. *Blood* 116: 1726–1733.

Takao, S. *et al.* (2010) The rapid induction of HLA-E is essential for the survival of antigen-activated naive CD4 T cells from attack by NK cells. *J. Immunol.* 185: 6031–6040.

Castriconi, R. *et al.* (2009) NK cells recognize and kill human glioblastoma cells with stem cell-like properties. *J. Immunol.* 182: 3530–3539.

Pérez-Martínez, A. *et al.* (2009) KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. *Pediatr. Blood Cancer* 53: 120–124.

Deniz, G. *et al.* (2008) Regulatory NK Cells suppress antigen-specific T cell responses. *J. Immunol.* 180: 850–857.

Wang, S. Y. *et al.* (2008) NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. *Blood* 111: 1456–1463.

Baltz, K. M. *et al.* (2007) Cancer immunoediting by GTR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. *FASEB J.* 21: 2442–2454.

Baratin, M. *et al.* (2007) Natural killer cell and macrophage cooperation in MyD88-dependent innate responses to *Plasmodium falciparum*. *J. Immunol.* 178: 85–94.

Chan, A. *et al.* (2007) CD56^{bright} human NK cells differentiate into CD56^{dim} cells: role of contact with peripheral fibroblasts. *J. Immunol.* 179: 89–94.

Chewning, J. H. *et al.* (2007) KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group *in vitro*. *J. Immunol.* 179: 854–868.

de Rham, C. *et al.* (2007) The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. *Arthritis Res.* 9: R125

Draghi, M. *et al.* (2007) NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection. *J. Immunol.* 178: 2688–2698.

Fauriat, C. *et al.* (2007) Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCR^{dull} phenotype induction. *Blood* 109: 323–330.

Romagnani, C. *et al.* (2007) CD56^{bright}CD16⁻ killer Ig-like receptor–NK cells display longer telomeres and acquire features of CD56^{dim} NK cells upon activation. *J. Immunol.* 178: 4947–4955.

Bielekova, B. *et al.* (2006) Regulatory CD56^{bright} natural killer cells mediate immunomodulatory effects of IL-2R α -targeted therapy (daclizumab) in multiple sclerosis. *Proc. Natl. Acad. Sci. U.S.A.* 130: 5941–5946.

Bryceson, Y. T. *et al.* (2006) Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. *Blood* 107: 159–166.

Della Chiesa, M. *et al.* (2006) Multidirectional interactions are bridging human NK cells with plasmacytoid and monocyte-derived dendritic cells during innate immune responses. *Blood* 108: 3851–3858.

CD56 MicroBeads (including CD56 MultiSort Kit)

Cella, M. *et al.* (2010) Expansion of human NK-22 cells with IL-7, IL-2, and IL-1 β reveals intrinsic functional plasticity. *Proc. Natl. Acad. Sci. USA* 107: 10961–10966.

Gruenbacher, G. *et al.* (2009) CD56⁺ human blood dendritic cells effectively promote TH1-type $\gamma\delta$ T-cell responses. *Blood* 114: 4422–4431.

Zhao, J. *et al.* (2009) Human pregnancy up-regulates Tim-3 in innate immune cells for systemic immunity. *J. Immunol.* 182: 6618–6624.

Cella, M. *et al.* (2008) A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. *Nature* 457: 722–725.

Roy, S. *et al.* (2008) NK Cells lyse T regulatory cells that expand in response to an intracellular pathogen. *J. Immunol.* 180: 1729–1736.

Cooley, S. *et al.* (2007) A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. *Blood* 110: 578–586.

Kurai, J. *et al.* (2007) Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. *Clin. Cancer Res.* 13: 1552–1561.

North, J. *et al.* (2007) Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. *J. Immunol.* 178: 85–89.

Poehlmann, T. G. *et al.* (2006) Inhibition of term decidual NK cell cytotoxicity by soluble HLA-G1. *Am. J. Reprod. Immunol.* 56: 275–285.

Sotiropoulou, P. A. *et al.* (2006) Interactions between human mesenchymal stem cells and natural killer cells. *Stem Cells* 24: 74–85.

Zhang, R. *et al.* (2006) Human NK cells positively regulate $\gamma\delta$ T cells in response to *Mycobacterium tuberculosis*. *J. Immunol.* 176: 2610–2616.

CD56 Whole Blood MicroBeads

André, M.C. *et al.* (2010) Long-term human CD34⁺ stem cell-engrafted nonobese diabetic/SCID/IL-2R γ^{null} mice show impaired CD8⁺ T cell maintenance and a functional arrest of immature NK cells. *J. Immunol.* 185: 2710–2720.

Willasch, A. *et al.* (2010) Enrichment of cell subpopulations applying automated MACS technique: purity, recovery and applicability for PCR-based chimerism analysis. *BMT* 45: 181–189.

Meyer, R. G. *et al.* (2007) Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. *Blood* 109: 374–382.

Cytokine secretion assays

Deniz, G. *et al.* (2008) Regulatory NK cells suppress antigen-specific T cell responses. *J. Immunol.* 180: 850–857.

de Rham, C. *et al.* (2007) The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. *Arthritis Res.* 9: R125

Morris, S. C. *et al.* (2006) IL-4 induces *in vivo* production of IFN- γ by NK and NKT cells. *J. Immunol.* 176: 5299–5305

KIR Typing Kit

André, M.C. *et al.* (2010) Long-term human CD34⁺ stem cell-engrafted nonobese diabetic/SCID/IL-2R γ^{null} mice show impaired CD8⁺ T cell maintenance and a functional arrest of immature NK cells. *J. Immunol.* 185: 2710–2720.

Siegler, U. *et al.* (2010) Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. *Cytotherapy* 12: 750–763.

Basu, D. *et al.* (2009) Stimulatory and inhibitory killer Ig-like receptor molecules are expressed and functional on lupus T cells. *J. Immunol.* 183: 2889–2890.

Pérez-Martínez, A. *et al.* (2009) KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. *Pediatr. Blood Cancer* 53: 120–124.

Mouse NK cells

NK Cell Isolation Kit

Chan, C. J. *et al.* (2010) DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. *J. Immunol.* 184: 902–911.

Lassen, M. G. *et al.* (2010) Intrahepatic IL-10 maintains NKG2A⁺Ly49⁻ liver NK cells in a functionally hyporesponsive state. *J. Immunol.* 184: 2693–2701.

Halfteck, G. *et al.* (2009) Enhanced *in vivo* growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1. *J. Immunol.* 182: 2221–2230.

Lundqvist, A. *et al.* (2009) Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. *Blood* 113: 6120–6127.

Sun, J.C. *et al.* (2009) Cutting edge: IL-15-independent NK cell response to mouse cytomegalovirus infection. *J. Immunol.* 183: 2911–2914.

Hallett, W.D. *et al.* (2008) Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. *J. Immunol.* 180: 163–170.

Sun, J. C. and Lanier, L. L. (2008) Tolerance of NK cells encountering their viral ligand during development. *J. Exp. Med.* 205: 1819–1828.

Takada, A. *et al.* (2008) Two novel NKG2D ligands of the mouse H60 family with differential expression patterns and binding affinities to NKG2D. *J. Immunol.* 180: 1678–1685.

Elsner, L. *et al.* (2007) The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. *J. Immunol.* 179: 5523–5533.

Huang, L. P. *et al.* (2007) Granulysin-mediated tumor rejection in transgenic mice. *J. Immunol.* 178: 77–84

Xu, J. *et al.* (2007) Essential role of the TNF-TNFR2 cognate interaction in mouse dendritic cell–natural killer cell crosstalk. *Blood* 109: 3333–3341.

CD49b (DX5) MicroBeads

Xie, X. *et al.* (2010) MHC class I D^k expression in hematopoietic and nonhematopoietic cells confers natural killer cell resistance to murine cytomegalovirus. *Proc. Natl. Acad. Sci. USA* 107: 8754–8759.

Zou, Y. *et al.* (2010) Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand contributes to hepatocyte necrosis in virus-induced liver failure. *J. Immunol.* 184: 466–475.

Hoover, R. *et al.* (2009) Impaired NK cytolytic activity and enhanced tumor growth in NK lytic-associated molecule-deficient mice. *J. Immunol.* 183: 6913–6921.

Lin, Y. *et al.* (2009) Prevention of embryo loss in non-obese diabetic mice using adoptive ITGA2⁺ISG20⁺ natural killer-cell transfer. *Reproduction* 137: 943–955.

Han, X. *et al.* (2008) NK cells contribute to intracellular bacterial infection-mediated inhibition of allergic responses. *J. Immunol.* 180: 4621–4628.

Alici, E. *et al.* (2007) Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model. *Exp. Hematology* 35: 1839–1846.

Blasius, A. L. *et al.* (2007) Development and function of murine B220⁺CD11c⁺NK1.1⁺ cells identify them as a subset of NK cells. *J. Exp. Med.* 204: 2561–2568.

Liu, C. *et al.* (2007) Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. *Blood* 109: 4336–4342.

Kim, N. *et al.* (2007) The p110 δ catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion. *Blood* 110: 3202–3208.



Miltenyi Biotec

Miltenyi Biotec GmbH
Friedrich-Ebert-Straße 68
51429 Bergisch Gladbach
Germany
Phone +49 2204 8306-0
Fax +49 2204 85197
macs@miltenyibiotec.de

Miltenyi Biotec Inc.
2303 Lindbergh Street
Auburn, CA 95602-9562, USA
Phone 800 FOR MACS
Phone +1 530 888 8871
Fax +1 530 888 8925
macs@miltenyibiotec.com

Miltenyi Biotec B.V. (Benelux)
macs@miltenyibiotec.nl
Customer service Netherlands
Phone 0800 4020120
Customer service Belgium
Phone 0800 94016
Customer service Luxembourg
Phone 800 24971

Miltenyi Biotec SAS (France)
Phone +33 1 56 98 16 16
macs@miltenyibiotec.fr

Miltenyi Biotec S.r.l. (Italy)
Phone +39 051 646 0411
macs@miltenyibiotec.it

Miltenyi Biotec K.K. (Japan)
Phone +81 3 5646 8910
macs@miltenyibiotec.jp

Miltenyi Biotec Asia Pacific Pte. Ltd. (Singapore)
Phone +65 6238 8183
macs@miltenyibiotec.com.sg

Miltenyi Biotec S.L. (Spain)
Phone +34 91 512 12 90
macs@miltenyibiotec.es

Miltenyi Biotec Ltd. (UK)
Phone +44 1483 799 800
macs@miltenyibiotec.co.uk

www.miltenyibiotec.com

Miltenyi Biotec Australia Pty. Ltd.
Phone +61 2 8877 7400
macs@miltenyibiotec.com.au

Miltenyi Biotec Trading (Shanghai) Co., Ltd. (P.R. China)
Phone +86 21 6235 1005
macs@miltenyibiotec.com.cn

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS and the MACS logo are registered trademarks of Miltenyi Biotec GmbH.